254 related articles for article (PubMed ID: 27233242)
1. Cost-effectiveness comparison of prophylactic octreotide and pasireotide for prevention of fistula after pancreatic surgery.
Welsch T; Müssle B; Distler M; Knoth H; Weitz J; Häckl D
Langenbecks Arch Surg; 2016 Nov; 401(7):1027-1035. PubMed ID: 27233242
[TBL] [Abstract][Full Text] [Related]
2. Selective Perioperative Administration of Pasireotide is More Cost-Effective Than Routine Administration for Pancreatic Fistula Prophylaxis.
Denbo JW; Slack RS; Bruno M; Cloyd JM; Prakash L; Fleming JB; Kim MP; Aloia TA; Vauthey JN; Lee JE; Katz MH
J Gastrointest Surg; 2017 Apr; 21(4):636-646. PubMed ID: 28050766
[TBL] [Abstract][Full Text] [Related]
3. The Cost of Postoperative Pancreatic Fistula Versus the Cost of Pasireotide: Results from a Prospective Randomized Trial.
Ma LW; Dominguez-Rosado I; Gennarelli RL; Bach PB; Gonen M; D'Angelica MI; DeMatteo RP; Kingham TP; Brennan MF; Jarnagin WR; Allen PJ
Ann Surg; 2017 Jan; 265(1):11-16. PubMed ID: 27429029
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic pasireotide administration following pancreatic resection reduces cost while improving outcomes.
Abbott DE; Sutton JM; Jernigan PL; Chang A; Frye P; Shah SA; Schauer DP; Eckman MH; Ahmad SA; Sussman JJ
J Surg Oncol; 2016 Jun; 113(7):784-8. PubMed ID: 27041733
[TBL] [Abstract][Full Text] [Related]
5. Pasireotide for the Prevention of Pancreatic Fistula Following Pancreaticoduodenectomy: A Cost-effectiveness Analysis.
Goyert N; Eeson G; Kagedan DJ; Behman R; Lemke M; Hallet J; Mittmann N; Law C; Karanicolas PJ; Coburn NG
Ann Surg; 2017 Jan; 265(1):2-10. PubMed ID: 27537539
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of the use of octreotide for prevention of complications following pancreatic resection.
Rosenberg L; MacNeil P; Turcotte L
J Gastrointest Surg; 1999; 3(3):225-32. PubMed ID: 10481115
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Pasireotide for Prevention of Postoperative Pancreatic Fistula in Pancreatic Surgery: a Systematic Review and Meta-analysis.
Liu X; Pausch T; Probst P; Cui J; Wei J; Hackert T; Miao Y
J Gastrointest Surg; 2020 Jun; 24(6):1421-1429. PubMed ID: 32207077
[TBL] [Abstract][Full Text] [Related]
8. Pasireotide is not effective in reducing the development of postoperative pancreatic fistula.
Young S; Sung ML; Lee JA; DiFronzo LA; O'Connor VV
HPB (Oxford); 2018 Sep; 20(9):834-840. PubMed ID: 30060910
[TBL] [Abstract][Full Text] [Related]
9. Meta-Analysis on the Effect of Pasireotide for Prevention of Postoperative Pancreatic Fistula.
Dalton EC; Johns MS; Rhodes L; Merritt WT; Petrelli NJ; Tiesi GJ
Am Surg; 2020 Dec; 86(12):1728-1735. PubMed ID: 32870029
[TBL] [Abstract][Full Text] [Related]
10. Octreotide and postoperative pancreatic fistula after pancreaticoduodenectomy: What we know so far? A narrative review.
Tilak M; Tewari M; Shukla HS
Indian J Cancer; 2023; 60(2):152-159. PubMed ID: 37530235
[TBL] [Abstract][Full Text] [Related]
11. Impact of pasireotide on postoperative pancreatic fistulas following distal resections.
Vuorela T; Mustonen H; Kokkola A; Haglund C; Seppanen H
Langenbecks Arch Surg; 2021 May; 406(3):735-742. PubMed ID: 33474568
[TBL] [Abstract][Full Text] [Related]
12. Octreotide prophylaxis is not beneficial for biochemical activity and clinical severity of postoperative pancreatic fistula after pancreatic surgery.
Droeser RA; Jeanmonod P; Schuld J; Moussavian MR; Schilling MK; Kollmar O
Dig Surg; 2012; 29(6):484-91. PubMed ID: 23392293
[TBL] [Abstract][Full Text] [Related]
13. Risk-stratified analysis of pasireotide for patients undergoing pancreatectomy.
Peng JS; Joyce D; Brady M; Groman A; Attwood K; Kuvshinoff B; Hochwald SN; Kukar M
J Surg Oncol; 2020 Aug; 122(2):195-203. PubMed ID: 32474957
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin analogues and the risk of post-operative pancreatic fistulas after pancreatic resection - A systematic review & meta-analysis.
Li T; D'Cruz RT; Lim SY; Shelat VG
Pancreatology; 2020 Mar; 20(2):158-168. PubMed ID: 31980352
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis on the Effect of Pasireotide for Prevention of Postoperative Pancreatic Fistula.
Dalton EC; Johns MS; Rhodes L; Merritt WT; Petrelli NJ; Tiesi GG
Am Surg; 2020 May; 86(5):429-436. PubMed ID: 32684027
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin and octreotide in the prevention of postoperative pancreatic complications and the treatment of enterocutaneous pancreatic fistulas: a systematic review of randomized controlled trials.
Li-Ling J; Irving M
Br J Surg; 2001 Feb; 88(2):190-9. PubMed ID: 11167865
[TBL] [Abstract][Full Text] [Related]
17. Systematic review and meta-analysis of somatostatin analogues in the prevention of postoperative complication after pancreaticoduodenectomy.
Jin K; Zhou H; Zhang J; Wang W; Sun Y; Ruan C; Hu Z; Wang Y
Dig Surg; 2015; 32(3):196-207. PubMed ID: 25872003
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin analogues for the prevention of pancreatic fistula after open pancreatoduodenectomy: A nationwide analysis.
Bootsma BT; Plat VD; van de Brug T; Huisman DE; Botti M; van den Boezem PB; Bonsing BA; Bosscha K; Dejong CHC; Groot-Koerkamp B; Hagendoorn J; van der Harst E; de Hingh IH; de Meijer VE; Luyer MD; Nieuwenhuijs VB; Pranger BK; van Santvoort HC; Wijsman JH; Zonderhuis BM; Kazemier G; Besselink MG; Daams F;
Pancreatology; 2022 Apr; 22(3):421-426. PubMed ID: 35304104
[TBL] [Abstract][Full Text] [Related]
19. The Use of Prophylactic Somatostatin Therapy Following Pancreaticoduodenectomy: A Meta-analysis of Randomised Controlled Trials.
Adiamah A; Arif Z; Berti F; Singh S; Laskar N; Gomez D
World J Surg; 2019 Jul; 43(7):1788-1801. PubMed ID: 30798417
[TBL] [Abstract][Full Text] [Related]
20. Perioperative application of somatostatin analogs for pancreatic surgery-current status in Germany.
Volk A; Nitschke P; Johnscher F; Rahbari N; Welsch T; Reißfelder C; Weitz J; Distler M; Mees ST
Langenbecks Arch Surg; 2016 Nov; 401(7):1037-1044. PubMed ID: 27628685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]